Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1Atrial Fibrillation 1

Interventions

Fluorouracil 14pembrolizumab 13Paclitaxel 13Oxaliplatin 13Leucovorin 10Carboplatin 9Radiotherapy 8Capecitabine 8Trastuzumab 7Nivolumab 7Drug Therapy 7Cisplatin 7Radiation 6Esophagectomy 6Taxes 5Specimen Handling 5Surgical Procedures, Operative 4Irinotecan 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Radiotherapy, Intensity-Modulated 3Proton Therapy 3Immunotherapy 3Blood Specimen Collection 3zanidatamab 2ulixertinib 2trastuzumab biosimilar HLX02 2relatlimab 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Amiodarone × 90 days × Clear all
NCT06067438 2026-05-22

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Atrial Fibrillation, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡